Pycnogenol (French Maritime Pine Bark Extract): What Conditions Have Real Trial Evidence

Pycnogenol is the trademarked name for a standardised extract from the bark of Pinus pinaster ssp. atlantica (French maritime pine), grown in southwestern France. It is a complex mixture of procyanidins, phenolic acids, and catechins, sold under a tight specification by a single manufacturer (Horphag Research). Because the formulation is standardised, the trial base is unusually internally consistent — though almost entirely funded by, or affiliated with, the maker.

Chronic venous insufficiency

The most replicated indication. Multiple RCTs and meta-analyses have shown improvements in leg swelling, heaviness, and ulcer healing in chronic venous insufficiency, at doses of 150–300 mg/day for 4–12 weeks. A Cochrane review concluded that Pycnogenol may improve leg pain and oedema versus placebo, though most included trials had risk-of-bias concerns related to sponsor involvement [1].

Endothelial function and blood pressure

Modest improvements in flow-mediated dilation and small reductions in systolic blood pressure (in the range of 3–6 mm Hg) have been reported across several trials in patients with mild hypertension or metabolic syndrome [2]. The effect size is similar to other polyphenol-rich extracts and far smaller than first-line antihypertensive drugs. Useful as an adjunct, not as monotherapy for hypertension.

Diabetic microvascular complications

Several trials in patients with type 2 diabetes have reported improvements in retinopathy progression, microcirculation, and HbA1c. The effects are modest (HbA1c reductions of 0.3–0.8%), comparable to dietary interventions, and most studies are open-label or small. A 2008 RCT in early diabetic retinopathy showed slowing of microaneurysm formation at 24 weeks [3].

Osteoarthritis

Two RCTs in knee osteoarthritis reported reductions in pain and improved WOMAC scores at doses of 100–150 mg/day over 12 weeks. Effects were of similar magnitude to glucosamine but trial sizes were small (n=37 to n=156) [4].

Cognitive performance

Several smaller trials have reported modest improvements in attention, working memory, and mood at doses of 150 mg/day in adults aged 35–60. None have been performed in dementia populations. The cognitive trial base is in healthy adults under stress conditions; effect sizes are small.

What the safety and interaction picture looks like

Pycnogenol is well tolerated; adverse events in trials are mild (GI upset, headache) and comparable to placebo. The most clinically relevant concern is platelet inhibition — at doses of 200 mg/day, ex vivo platelet aggregation is reduced, and the maker recommends caution with anticoagulants and antiplatelet drugs and discontinuation 1–2 weeks before elective surgery [5]. People on warfarin, DOACs, or aspirin should discuss combined use with their clinician.

What it is not

Pycnogenol is not a cure for any of the listed conditions. The effect sizes are modest and the funding pattern means published positive trials should be read with care. For venous insufficiency, the evidence is the strongest and competing first-line therapies (compression stockings) remain superior. For metabolic conditions, lifestyle and pharmacotherapy remain primary.

Dosing across indications

50 mg three times daily (150 mg/day) is the most commonly used dose in published trials. Higher doses (200–300 mg/day) are used in venous insufficiency and severe diabetic microangiopathy. A 6–12 week trial is reasonable for symptomatic conditions like leg swelling or knee pain. There is no rationale for indefinite use without symptomatic benefit.

The funding picture is unusually concentrated

Pycnogenol's clinical research is dominated by one industry sponsor (Horphag Research) and a small number of recurring academic collaborators, particularly the Belcaro group in Italy. The funding pattern does not by itself invalidate the findings — the trials are placebo-controlled and randomised — but it does mean that independent replication is sparse. The most credible indications are those where systematic reviews from independent groups (Cochrane, Annals reviews) have evaluated the literature and found consistent direction of effect. Chronic venous insufficiency is in this category. For other indications, individual positive trials should be read with awareness that selective publication is a possibility.